Endocannabinoid System in Neurodegeneration

Endocannabinoid System in Neurodegeneration

Introduction

The endocannabinoid system (ECS) is a ubiquitous lipid-based neuromodulatory system comprising cannabinoid receptors (CB1R and CB2R), endogenous lipid ligands (endocannabinoids), and the enzymatic machinery for their synthesis and degradation. The ECS plays fundamental roles in synaptic transmission, [neuroinflammation](/mechanisms/neuroinflammation), [oxidative stress](/mechanisms/oxidative-stress) regulation, and neuronal survival across the central nervous system. Dysregulation of endocannabinoid signaling has been implicated in virtually all major [neurodegenerative diseases](/diseases), including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [Huntington's disease](/mechanisms/huntington-pathway), [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis), and [multiple sclerosis](/diseases/multiple-sclerosis)[@marzo2015].

Endocannabinoid System in Neurodegeneration

Introduction

The endocannabinoid system (ECS) is a ubiquitous lipid-based neuromodulatory system comprising cannabinoid receptors (CB1R and CB2R), endogenous lipid ligands (endocannabinoids), and the enzymatic machinery for their synthesis and degradation. The ECS plays fundamental roles in synaptic transmission, [neuroinflammation](/mechanisms/neuroinflammation), [oxidative stress](/mechanisms/oxidative-stress) regulation, and neuronal survival across the central nervous system. Dysregulation of endocannabinoid signaling has been implicated in virtually all major [neurodegenerative diseases](/diseases), including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [Huntington's disease](/mechanisms/huntington-pathway), [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis), and [multiple sclerosis](/diseases/multiple-sclerosis)[@marzo2015].

The brain is one of the most cannabinoid receptor-rich organs in the body, with CB1R being the most abundant G protein-coupled receptor (GPCR) in the mammalian brain. CB1R density is particularly high in the [hippocampus](/brain-regions/hippocampus), [basal ganglia](/brain-regions/basal-ganglia), [cerebellum](/brain-regions/cerebellum), and [cerebral cortex](/brain-regions/cortex) — regions that are selectively affected in different neurodegenerative conditions. CB2R, historically considered a peripheral immune receptor, is now recognized to be expressed on [microglia](/cell-types/microglia) and [reactive astrocytes](/cell-types/astrocytes)[@solas2013].

Cannabinoid Receptor Table

| Receptor | Type | Brain Distribution | Function | Signaling |
|----------|------|-------------------|----------|-----------|
| CB1R (CNR1) | GPCR, Gi/o-coupled | [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), basal ganglia, cerebellum, hypothalamus | Retrograde synaptic signaling, neurotransmitter release inhibition, synaptic plasticity | Gi/o → ↓cAMP, ↓Ca²⁺, ↑K⁺, ↑MAPK |
| CB2R (CNR2) | GPCR, Gi/o-coupled | [microglia](/cell-types/microglia) and reactive astrocytes | Immunomodulation, inflammation resolution | Gi/o → ↓cAMP, cytokine reduction |

CB2R expression in the brain was long debated but is now firmly established, particularly on [microglia](/cell-types/microglia) and reactive [astrocytes](/cell-types/astrocytes). CB2R is markedly upregulated during neuroinflammation and neurodegeneration, where it functions as an endogenous brake on microglial M1 polarization and pro-inflammatory cytokine release. CB2R activation shifts [microglia](/cell-types/microglia) toward an anti-inflammatory, phagocytic phenotype (M2-like), promoting clearance of [amyloid-beta](/proteins/amyloid-beta) plaques and cellular debris while reducing TNF-α, IL-1β, and IL-6 secretion[@solas2013].

Endocannabinoids

The two principal endocannabinoids are anandamide (AEA) and 2-arachidonoylglycerol (2-AG)[@chen2012]:

Anandamide (N-arachidonoylethanolamine, AEA) is synthesized from N-arachidonoyl phosphatidylethanolamine (NAPE) by NAPE-specific phospholipase D (NAPE-PLD). AEA is a partial agonist at CB1R with relatively high affinity (Ki ~60–90 nM) and low efficacy, and also activates TRPV1 channels and PPARγ nuclear receptors. AEA is rapidly degraded by fatty acid amide hydrolase (FAAH), which is located on the endoplasmic reticulum membrane of postsynaptic [neurons](/entities/neurons)[@pisani2011][@marzo2015][@blzquez2011].

2-Arachidonoylglycerol (2-AG) is the most abundant endocannabinoid in the brain (present at ~1000× higher concentrations than AEA) and is a full agonist at both CB1R and CB2R. 2-AG is synthesized from membrane phospholipids by diacylglycerol lipase-alpha (DAGLα) in a two-step process: phospholipase C (PLC) hydrolyzes phosphoinositides to generate diacylglycerol (DAG), which DAGLα then converts to 2-AG. 2-AG is primarily degraded by monoacylglycerol lipase (MAGL), which is localized to presynaptic terminals and accounts for ~85% of 2-AG hydrolysis, with additional contributions from ABHD6 and ABHD12[@morenomartet2014][@marzo2015][@pryce2015].

Enzymatic Machinery

| Enzyme | Function | Localization | Pharmacological Inhibitors |
|--------|----------|-------------|---------------------------|
| NAPE-PLD | Synthesizes AEA from NAPE | Postsynaptic membranes | — |
| DAGLα | Synthesizes 2-AG from DAG | Postsynaptic [dendritic spines](/cell-types/dendritic-spines-neurodegeneration) | DO34, DH376 |
| FAAH | Degrades AEA (and other N-acylethanolamines) | Postsynaptic ER membranes | URB597, PF-04457845, JNJ-42165279 |
| MAGL | Degrades 2-AG → arachidonic acid + glycerol | Presynaptic terminals, astrocytes | JZL184, ABX-1431, Lu AG06466 |
| ABHD6 | Degrades 2-AG (postsynaptic pool) | Postsynaptic membranes | WWL70 |
| ABHD12 | Degrades 2-AG | Microglial membranes | — |

ECS Dysregulation in Neurodegenerative Diseases

Alzheimer's Disease

In [Alzheimer's disease](/diseases/alzheimers-disease), ECS dysregulation is extensive and progressive. Key findings include:

• CB1R downregulation: CB1R expression and binding are reduced in the [hippocampus](/brain-regions/hippocampus) and cortical regions of AD patients, correlating with [Braak staging](/mechanisms/braak-staging) and cognitive decline. CB1R-positive neurons are preferentially lost in cortical layers II–III of the entorhinal [cortex](/brain-regions/cortex). However, remaining CB1R on surviving neurons may be functionally impaired due to uncoupling from Gi/o proteins[@solas2013].
• CB2R upregulation: CB2R expression is markedly increased on activated [microglia](/cell-types/microglia-neuroinflammation) surrounding [amyloid-beta](/proteins/amyloid-beta) plaques and in areas of tau pathology. This upregulation represents an endogenous anti-inflammatory response that may be therapeutically amplifiable.
• Altered endocannabinoid levels: AEA levels are reduced in cortex and hippocampus in AD, while FAAH expression and activity are increased in reactive astrocytes surrounding amyloid plaques. 2-AG levels show variable changes depending on disease stage and brain region.
• [Aβ](/proteins/amyloid-beta)-ECS interactions: [Amyloid-Beta](/proteins/amyloid-beta) peptides directly interact with CB1R, impairing its signaling. Additionally, [Aβ](/proteins/amyloid-beta) activates FAAH, accelerating AEA degradation and reducing endocannabinoid tone. Conversely, CB1R and CB2R activation reduces Aβ production by modulating [APP](/entities/app) processing via [γ-secretase](/entities/gamma-secretase) regulation and enhances microglial phagocytosis of existing Aβ deposits[@bedse2024].
• MAGL-arachidonic acid link: MAGL hydrolysis of 2-AG generates arachidonic acid, the precursor for prostaglandins and other pro-inflammatory eicosanoids. MAGL inhibition therefore simultaneously elevates neuroprotective 2-AG and reduces pro-inflammatory prostaglandin synthesis — a dual benefit for AD[@chen2012].

Parkinson's Disease

The ECS is intimately linked to [basal ganglia](/brain-regions/basal-ganglia) circuitry and [dopaminergic neurodegeneration](/mechanisms/dopaminergic-neurodegeneration):

• Endocannabinoid hyperactivity in striatum: In PD, loss of dopaminergic input to the [striatum](/brain-regions/striatum) leads to compensatory upregulation of endocannabinoid signaling in the indirect pathway (striatopallidal) medium spiny neurons. Elevated 2-AG and AEA levels in the striatum contribute to excessive CB1R-mediated inhibition of GABAergic transmission, exacerbating motor symptoms[@pisani2011].
• CB2R on activated microglia: CB2R is upregulated on microglia in the [substantia nigra](/brain-regions/substantia-nigra) of PD patients and in animal models. CB2R activation reduces microglial NADPH oxidase activity, suppresses [neuroinflammation](/mechanisms/neuroinflammation), and protects dopaminergic neurons in MPTP and 6-OHDA models.
• TRPV1 involvement: TRPV1 channels on nigrostriatal dopaminergic neurons modulate dopamine release and are potential therapeutic targets in PD.
• Levodopa-induced dyskinesia: Endocannabinoid signaling modulates the development and expression of levodopa-induced dyskinesias (LID), with CB1R antagonists showing anti-dyskinetic effects in animal models[@pisani2011].

Huntington's Disease

[Huntington's disease](/mechanisms/huntington-pathway) shows the most dramatic ECS changes among neurodegenerative conditions:

• Early CB1R loss: CB1R downregulation in the caudate-putamen and [globus pallidus](/brain-regions/globus-pallidus) is one of the earliest molecular changes in HD, occurring before the onset of motor symptoms and preceding neuronal death. Mutant [huntingtin](/proteins/huntingtin) directly represses CB1R gene (CNR1) transcription.
• Loss of protective tone: Reduced CB1R signaling impairs neuroprotective retrograde endocannabinoid signaling, contributing to excitotoxic vulnerability of medium spiny neurons in the striatum[@blzquez2011].
• CB2R therapeutic potential: CB2R activation in HD models reduces microglial activation, decreases mutant [huntingtin](/proteins/huntingtin) aggregation, and improves motor function. Selective CB2R agonists are under investigation.

Amyotrophic Lateral Sclerosis

In [ALS](/diseases/amyotrophic-lateral-sclerosis), both pharmacological agonists of CB1R and CB2R and elevated levels of AEA (via FAAH inhibition) exert anti-inflammatory and neuroprotective effects, delaying disease progression in SOD1-G93A transgenic mouse models. Endocannabinoid levels are elevated in the spinal cord of ALS patients, potentially representing an endogenous protective response. CB2R activation on spinal microglia reduces pro-inflammatory cytokine release and delays motor neuron degeneration[@morenomartet2014].

Multiple Sclerosis

In [multiple sclerosis](/diseases/multiple-sclerosis), endocannabinoids modulate immune cell trafficking, T-cell proliferation, and [demyelination](/mechanisms/demyelination). Nabiximols (Sativex), a cannabinoid-based medication containing THC and CBD in a 1:1 ratio, is approved in several countries for MS-associated spasticity. CB2R activation reduces inflammatory infiltrates and promotes remyelination in experimental autoimmune encephalomyelitis (EAE) models[@pryce2015].

Neuroprotective Mechanisms of the ECS

Anti-Excitotoxic Effects

CB1R activation on presynaptic glutamatergic terminals suppresses excessive glutamate release, providing direct protection against [excitotoxicity](/mechanisms/excitotoxicity). This retrograde inhibition is particularly important in conditions where glutamatergic overactivity drives neuronal death, such as ischemia, epilepsy, and AD. CB1R agonists reduce NMDA receptor-mediated calcium influx and prevent excitotoxic cascades in hippocampal and cortical neurons[@solas2013].

Anti-Inflammatory Modulation

The ECS modulates [neuroinflammation](/mechanisms/neuroinflammation) through multiple pathways:

• CB2R-mediated microglial polarization: Shifts microglia from pro-inflammatory (M1) to anti-inflammatory (M2) phenotype, reducing TNF-α, IL-1β, IL-6, iNOS, and COX-2 expression while increasing IL-10, IL-4, and arginase-1
• [NF-κB](/mechanisms/nf-kb-pathway) suppression: Both CB1R and CB2R activation inhibit NF-κB signaling, reducing transcription of pro-inflammatory genes
• [NLRP3 inflammasome](/mechanisms/nlrp3-inflammasome) inhibition: Endocannabinoids suppress NLRP3 inflammasome assembly and IL-1β maturation in microglia
• PPARγ activation: AEA and certain synthetic cannabinoids activate PPARγ, a master regulator of anti-inflammatory gene expression
• Prostaglandin reduction: MAGL inhibition reduces arachidonic acid availability for COX-mediated prostaglandin synthesis[@chen2012]

Antioxidant Properties

Cannabinoids provide neuroprotection against [oxidative stress](/mechanisms/oxidative-stress) through both receptor-dependent and receptor-independent mechanisms. CB1R signaling activates the PI3K/Akt/Nrf2 pathway, upregulating antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase). Additionally, the phenolic ring structure of certain cannabinoids (e.g., cannabidiol) allows direct scavenging of reactive oxygen species independently of receptor activation[@bedse2024].

Neurotrophic Support

Endocannabinoid signaling enhances the expression and release of [neurotrophic factors](/mechanisms/neurotrophic-factors), including brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), and nerve growth factor (NGF). CB1R activation stimulates BDNF expression through ERK1/2-CREB signaling, supporting neuronal survival and [synaptic plasticity](/mechanisms/synaptic-plasticity)[@de2010].

Therapeutic Strategies Targeting the ECS

FAAH Inhibitors

Inhibition of FAAH elevates endogenous AEA levels without the psychoactive effects of direct CB1R agonists:

| Compound | Status | Key Findings |
|----------|--------|-------------|
| URB597 | Preclinical | Reduces Aβ-induced neuroinflammation and cognitive deficits in AD models; neuroprotective in PD models |
| PF-04457845 | Phase I (completed) | Potent, selective, irreversible FAAH inhibitor; well-tolerated in humans; failed to show efficacy for cannabis dependence |
| JNJ-42165279 | Phase II | Evaluated for depressive disorders; potential AD applications |
| BIA 10-2474 | Discontinued | Fatal adverse events in Phase I (off-target serine hydrolase inhibition, not FAAH-specific) |

MAGL Inhibitors

MAGL inhibition elevates 2-AG and simultaneously reduces pro-inflammatory prostaglandins by limiting arachidonic acid supply:

| Compound | Status | Key Findings |
|----------|--------|-------------|
| JZL184 | Preclinical | Reduces neuroinflammation, Aβ pathology, and cognitive decline in AD mouse models; neuroprotective in MPTP PD models |
| ABX-1431 (Lu AG06466) | Phase II | First-in-class MAGL inhibitor in clinical trials; evaluated for Tourette syndrome and neurological disorders |
| FAAH/MAGL dual inhibitor | Phase I (NCT06808984) | Under investigation for agitation in AD |

CB2R-Selective Agonists

CB2R agonists offer anti-inflammatory neuroprotection without CB1R-mediated psychoactive effects:

• JWH-133: Reduces microglial activation and Aβ toxicity in AD models
• HU-308: Protects dopaminergic neurons in PD models
• GW405833 (L-768242): Reduces neuroinflammation in EAE (MS model)
• Lenabasum (JBT-101, Anabasum): CB2R agonist in clinical trials for inflammatory conditions[@cristino2020]

Phytocannabinoids

Cannabidiol (CBD) is non-psychoactive and acts through multiple ECS and non-ECS targets (negative allosteric modulator of CB1R, inverse agonist at CB2R, FAAH inhibitor, TRPV1 agonist, 5-HT1A agonist, GPR55 antagonist, PPARγ agonist). CBD shows neuroprotective effects in models of AD, PD, HD, ALS, and MS through anti-inflammatory, antioxidant, and anti-excitotoxic mechanisms.

Δ⁹-Tetrahydrocannabinol (THC) is a partial CB1R/CB2R agonist that, at low doses, enhances Aβ clearance and reduces [tau hyperphosphorylation](/mechanisms/tau-pathway) in AD models. Nabiximols (THC:CBD 1:1) is approved for MS spasticity in several countries[@pryce2015].

Challenges and Future Directions

Several challenges limit translation of ECS-based therapeutics to neurodegenerative diseases:

External Links

• [NIH: Endocannabinoid System](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877694/)
• [IUPHAR/BPS Guide to Pharmacology: Cannabinoid Receptors](https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=13)
• [Cannabinoid Research Society](https://www.icrs.co/)

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Amyloid-Beta Aggregation](/mechanisms/amyloid-aggregation)
• [Tau Pathology](/mechanisms/tau-pathway)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [ALS](/diseases/amyotrophic-lateral-sclerosis)
• [Huntington's Disease](/mechanisms/huntington-pathway)
• [neuroinflammation](/mechanisms/neuroinflammation)
• [Microglia](/entities/microglia)
• [Astrocytes](/entities/astrocytes)
• [Synaptic Dysfunction](/mechanisms/synaptic-dysfunction)

Endocannabinoid Signaling Flowchart

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
• [BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/) - Developmental gene expression data

References